Nebraska Medicine achieves Stage 7 on EMRAM scale

Nebraska Medicine, comprising the University of Nebraska Medical Center, Bellevue Medical Center and UNMC Physicians, is the latest provider recognized for achieving Stage 7 on HIMSS Analytics' Electronic Medical Record Adoption Model.

Only 4.1 percent of the 5,400 U.S. hospitals in the HIMSS Analytics Database achieve the award for EMR adoption.

"We are delighted to achieve this milestone, showcasing our dedication to quality and patient care," said Nebraska Medicine Interim CEO Rosanna Morris in a statement. "Nebraska Medicine continues to dedicate time, talent and resources to the development and integration of our electronic medical record, in order to provide the highest quality of care to our patients."

Nebraska Medicine employs more than 1,000 physicians in the Omaha region and serves more than 500,000 patients annually. The IT department is led by Chief Transformation Officer Michael Ash, MD.

The health system uses a single, integrated Epic EMR, the result of an $87 million investment in 2012. Nebraska Medicine continues to add to the system, including a 2013 introduction of One Chart, an EHR system designed to boost communication between patients and providers.

"Nebraska Medicine has effectively developed its governance, clinical and business analytics and disaster recovery/business continuity strategies in a way that helps to ensure process improvements are sustainable," said John H. Daniels, global vice president, healthcare advisory services group, HIMSS Analytics.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.